Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2018

Burosumab therapy in children with x-linked hypophosphatemia
Thomas O. Carpenter
Yale University School of Medicine

Michael P. Whyte
Washington University School of Medicine in St. Louis

Erik A. Imel
Indiana University School of Medicine

Annemieke M. Boot
University of Groningen

Wolfgang Hogler
Birmingham Children's Hospital

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Carpenter, Thomas O.; Whyte, Michael P.; Imel, Erik A.; Boot, Annemieke M.; Hogler, Wolfgang; Linglart,
Agnes; Padidela, Raja; van't Hoff, William; Mao, Meng; Chen, Chao-Yin; Skrinar, Alison; Kakkis, Emil; Martin,
Javier San; and Portale, Anthony A., ,"Burosumab therapy in children with x-linked hypophosphatemia."
The New England Journal of Medicine. 378,21. 1987-1998. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/6845

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Thomas O. Carpenter, Michael P. Whyte, Erik A. Imel, Annemieke M. Boot, Wolfgang Hogler, Agnes Linglart,
Raja Padidela, William van't Hoff, Meng Mao, Chao-Yin Chen, Alison Skrinar, Emil Kakkis, Javier San
Martin, and Anthony A. Portale

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/6845

The

n e w e ng l a n d j o u r na l

of

m e dic i n e

Original Article

Burosumab Therapy in Children
with X-Linked Hypophosphatemia
Thomas O. Carpenter, M.D., Michael P. Whyte, M.D., Erik A. Imel, M.D.,
Annemieke M. Boot, M.D., Ph.D., Wolfgang Högler, M.D.,
Agnès Linglart, M.D., Ph.D., Raja Padidela, M.D., William van’t Hoff, M.D.,
Meng Mao, Ph.D., Chao‑Yin Chen, Ph.D., Alison Skrinar, Ph.D.,
Emil Kakkis, M.D., Ph.D., Javier San Martin, M.D., and Anthony A. Portale, M.D.

A BS T R AC T
BACKGROUND

X-linked hypophosphatemia is characterized by increased secretion of fibroblast growth
factor 23 (FGF-23), which leads to hypophosphatemia and consequently rickets, osteomalacia, and skeletal deformities. We investigated burosumab, a monoclonal antibody that
targets FGF-23, in patients with X-linked hypophosphatemia.
METHODS

In an open-label, phase 2 trial, we randomly assigned 52 children with X-linked hypophosphatemia, in a 1:1 ratio, to receive subcutaneous burosumab either every 2 weeks or
every 4 weeks; the dose was adjusted to achieve a serum phosphorus level at the low end
of the normal range. The primary end point was the change from baseline to weeks 40
and 64 in the Thacher rickets severity total score (ranging from 0 to 10, with higher scores
indicating greater disease severity). In addition, the Radiographic Global Impression of
Change was used to evaluate rachitic changes from baseline to week 40 and to week 64.
Additional end points were changes in pharmacodynamic markers, linear growth, physical ability, and patient-reported outcomes and the incidence of adverse events.
RESULTS

The mean Thacher rickets severity total score decreased from 1.9 at baseline to 0.8 at week
40 with every-2-week dosing and from 1.7 at baseline to 1.1 at week 40 with every-4-week
dosing (P<0.001 for both comparisons); these improvements persisted at week 64. The
mean serum phosphorus level increased after the first dose in both groups, and more than
half the patients in both groups had levels within the normal range (3.2 to 6.1 mg per
deciliter [1.0 to 2.0 mmol per liter]) by week 6. Stable serum phosphorus levels were maintained through week 64 with every-2-week dosing. Renal tubular phosphate reabsorption
increased from baseline in both groups, with an overall mean increase of 0.98 mg per
deciliter (0.32 mmol per liter). The mean dose of burosumab at week 40 was 0.98 mg per
kilogram of body weight with every-2-week dosing and 1.50 mg per kilogram with every4-week dosing. Across both groups, the mean serum alkaline phosphatase level decreased
from 459 U per liter at baseline to 369 U per liter at week 64. The mean standing-height
z score increased in both groups, with greater improvement seen at all time points with
every-2-week dosing (an increase from baseline of 0.19 at week 64) than with every-4-week
dosing (an increase from baseline of 0.12 at week 64). Physical ability improved and pain
decreased. Nearly all the adverse events were mild or moderate in severity.
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CONCLUSIONS

In children with X-linked hypophosphatemia, treatment with burosumab improved renal
tubular phosphate reabsorption, serum phosphorus levels, linear growth, and physical
function and reduced pain and the severity of rickets. (Funded by Ultragenyx Pharmaceutical and Kyowa Hakko Kirin; ClinicalTrials.gov number, NCT02163577; EudraCT number,
2014-000406-35).
n engl j med 378;21
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A Quick Take
is available at
NEJM.org

-linked hypophosphatemia, a disorder of renal phosphate wasting and the
most common heritable form of rickets,
is caused by loss-of-function mutations in the
gene encoding phosphate-regulating endopeptidase homolog X-linked (PHEX), which results in
excess circulating fibroblast growth factor 23
(FGF-23).1 FGF-23 is the primary regulator of
phosphate homeostasis and acts by controlling
phosphate reabsorption in the kidney.2 Excess
FGF-23 impairs renal phosphate reabsorption,
which leads to hypophosphatemia, and decreases
the synthesis of the active metabolite of vitamin D, 1,25-dihydroxyvitamin D (also known as
1,25[OH]2D). Chronic hypophosphatemia leads
to rickets and osteomalacia, which often result
in stunted growth, lower-limb deformity, pain,
and physical dysfunction that can limit daily
activities.1,3-5
Conventional therapy for X-linked hypophosphatemia consists of multiple daily doses of oral
phosphate salts and vitamin D metabolites or
analogues as replacement therapy.6 This treatment, which has been in place for approximately
four decades, transiently increases serum phosphorus levels; however, it is associated with
incomplete healing of rickets, residual skeletal
deformity, persistent short stature, gastrointestinal side effects, and risks of metabolic and endocrine abnormalities such as hypercalciuria,
nephrocalcinosis, and hyperparathyroidism.1,5,7-12
Burosumab is a recombinant human IgG1
monoclonal antibody that targets FGF-23.13,14 In
phase 1 and 2 trials involving adults with X-linked
hypophosphatemia, treatment with burosumab,
administered at doses of up to 1 mg per kilogram of body weight every 4 weeks, improved
renal tubular phosphate reabsorption, thereby
increasing serum phosphorus to normal levels,
and increased serum 1,25-dihydroxyvitamin D
levels.13-15 Here, we report the results of a clinical
trial that evaluated the efficacy and safety of
burosumab in pediatric patients with X-linked
hypophosphatemia.

Me thods
Patients

Children between 5 and 12 years of age were
eligible for participation if they had received a
diagnosis of X-linked hypophosphatemia; if they
had active rickets at growth plates, bowing of
1988
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the femur or tibia, or both; and if their pubertal
stage was classified as Tanner stage 2 or lower
(with stages ranging from 1 to 5 and higher
stages indicating more advanced pubertal development). X-linked hypophosphatemia was confirmed either by the presence of the PHEX mutation in the patient or a directly related family
member or by a serum intact FGF-23 level of
more than 30 pg per milliliter.16,17 Additional inclusion criteria were a fasting serum phosphorus
level of 2.8 mg or less per deciliter (0.90 mmol
per liter) and a standing height below the 50th
percentile for age and sex on the basis of local
normative data from the United States or Europe.
After the initial 36 patients were enrolled, another 16 patients were enrolled to provide additional safety and efficacy data. The 16 additional
patients were required to have a Thacher rickets
severity total score of at least 1.5 at the knee.18
Thacher rickets severity total score ranges from
0 (no rickets) to 10 (severe rickets); scores between 0 and 5 are typically observed in children
with the form of rickets assessed in this trial.
All the participants discontinued the conventional therapy they were receiving for X-linked
hypophosphatemia for the duration of the trial.
Key exclusion criteria were the use of vitamin D
metabolites or analogues within 14 days before
screening; the use of oral phosphate supplements, aluminum hydroxide antacids, systemic
glucocorticoids, or thiazide diuretics within 7 days
before screening; the use of growth hormone
therapy within 3 months before screening; nephrocalcinosis of grade 3 or higher as assessed by
renal ultrasonography19; hypocalcemia or hypercalcemia; tertiary hyperparathyroidism as determined by the investigator; or the use of calcimimetic agents within 2 months before screening.
Trial Design

In this randomized, open-label, parallel-group,
phase 2 trial, we investigated the efficacy and
safety of burosumab in children with X-linked
hypophosphatemia at nine sites in the United
States and Europe (see the Supplementary Appendix, available with the full text of this article
at NEJM.org). Patients were randomly assigned,
in a 1:1 ratio, to receive burosumab subcutaneously every 2 weeks or every 4 weeks during a
16-week dose-escalation period, followed by a
48-week treatment period, for a total of 64 weeks
of treatment. Patients had the option to enroll in
nejm.org
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an open-label extension. Enrollment of the initial
36 patients could include no more than 20 boys
or 20 girls.
After the initial doses of burosumab (0.1 mg
per kilogram every 2 weeks or 0.2 mg per kilogram every 4 weeks) were administered and no
severe side effects were observed, patients were
assigned sequentially to receive escalating doses
(0.2 or 0.3 mg per kilogram every 2 weeks, or 0.4
or 0.6 mg per kilogram every 4 weeks). During
the dose-escalation period, the dose was adjusted
according to the patient’s fasting serum phosphorus level 2 weeks after administration, with
a goal of attaining a phosphorus level at the low
end of the normal range (see the Supplementary
Appendix).
Trial End Points

The primary end point was the change from
baseline (with baseline scores determined according to radiographs obtained at screening) to
week 40 and week 64 in the Thacher rickets severity total score, as determined by an independent central reader who was unaware of the
treatment assignments; scores reflected combined assessments of prespecified radiographic
abnormalities at the wrist and knee.18 In addition, the Radiographic Global Impression of
Change was used to evaluate rachitic changes
from baseline to week 40 and to week 64; three
radiologists who were unaware of the treatment
assignments each provided scores, which were
subsequently averaged. The Radiographic Global
Impression of Change scale is a tool that enables
a side-by-side comparison of radiographs obtained
before and after treatment and is based on a
7-point ordinal scale that ranges from 3 (complete healing) to −3 (severe worsening). An assessment of deformities of the legs was also
performed with the use of the Radiographic
Global Impression of Change scale.20
Secondary end points included the change
from baseline in the following pharmacodynamic variables: the renal tubular phosphate
reabsorption (expressed as the ratio of the
maximum rate of tubular reabsorption of phosphate to the glomerular filtration rate), the
serum phosphorus level, the serum 1,25-dihydroxyvitamin D level, and the serum alkaline
phosphatase level (a marker of rachitic activity);
all serum and urine samples for these assessments were obtained during fasting.18,21-24 Addin engl j med 378;21

tional details of the trial methods and the timing
of assessments are available in the Supplementary Text section and Table S1 in the Supplementary Appendix. We also assessed the height-forage z score, physical ability (as evaluated with
the use of the 6-minute walk test), and patientreported pain and functional disability (as measured with the use of the Pediatric Orthopedic
Society of North America Pediatric Outcomes
Data Collection Instrument; normative scores
range from 0 to 100, with higher scores indicating better functioning or less pain).25-27
All reported adverse events and serious adverse events were tabulated. Changes in levels of
serum calcium and serum intact parathyroid
hormone and in urinary excretion of calcium
were determined. Urinary phosphorus was measured to calculate the ratio of the maximum rate
of tubular reabsorption of phosphate to the glomerular filtration rate. Serial assessments of the
development of both immunoreactive and neutralizing antibodies to burosumab were performed.
Evidence of ectopic calcification was evaluated
by renal and cardiac ultrasonography.19
Trial Oversight

The institutional review board at each participating site approved the protocol, available at
NEJM.org. Parents or guardians provided written informed consent for their children to participate, and when age-appropriate, the patient’s
assent was obtained before participation. An
external data and safety monitoring committee
monitored patient safety. The trial investigators
and the sponsors, Ultragenyx Pharmaceutical and
Kyowa Hakko Kirin, designed the trial and collected, analyzed, and interpreted the data. The
authors made the decision to submit the manuscript for publication and vouch for the completeness and accuracy of the data and for the
fidelity of the trial to the protocol. The manuscript was written by the authors with medical
writing support from the sponsors.
Statistical Analysis

For all the analyses of pharmacodynamic markers, P values were calculated for the mean change
from baseline to week 40 with the use of paired
Student’s t-tests. For the analysis of the Thacher
rickets severity total score, we calculated P values
and 95% confidence intervals for the least-squares
mean change from baseline to week 40 using
nejm.org
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the generalized estimating equation approach,
which included regimen, trial visit, baseline
Thacher rickets severity total score, and the interaction between regimen and trial visit as categorical variables, with an exchangeable covariance
structure. All other assessments were reported
as means and standard deviations, least-squares
means and standard errors, or changes from
baseline. For the analyses of the Thacher rickets
severity total score, serum phosphorus level, renal
tubular phosphate reabsorption, 1,25-dihydroxy
vitamin D level, and serum alkaline phosphatase
level, P values for the mean change from baseline in each dosing group at week 40 are presented as nominal P values.
We estimated that a sample of 50 patients
would provide the trial with at least 90% power
to detect a mean (±SD) change from baseline of
0.5±0.5 in the Thacher rickets severity total
score. Nominal two-sided P values of 0.05 or less
were considered to indicate statistical significance.

R e sult s
Patients

A total of 79 children were screened, of whom
52 (66%) were eligible for participation and were
randomly assigned to receive burosumab either
every 2 weeks or every 4 weeks (26 patients in
each group). All 52 patients completed 64 weeks
of treatment, were included in the efficacy and
safety analyses, and continued into the extension period.
Overall, the demographic and clinical characteristics of the two groups were similar at baseline, although standing height was slightly greater in the every-2-week dosing group (Table 1). At
baseline, patients had persistent rickets, bowing
of the femur or tibia, or both, as well as short
stature, even though 96% had received previous
conventional therapy for X-linked hypophosphatemia for a mean of 6.9 years. At baseline, 94%
of the patients had active rickets at growth plate
sites (Thacher rickets severity total score >0).
Baseline radiographs revealed that many patients
had metaphyseal abnormalities at the distal femur (lucency, 98%; separation, 100%; fraying,
89%; and concavity, 89%), proximal tibia (lucency, 89%; separation, 85%; fraying, 67%; and
concavity, 79%), distal ulna (lucency, 85%; sepa-
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ration, 73%; fraying, 54%; and concavity, 83%),
and distal radius (lucency, 60%; separation, 50%;
fraying, 35%; and concavity, 39%).
Efficacy

By week 40, rickets was significantly ameliorated,
with a mean Thacher rickets severity total score
of 0.8 in the every-2-week dosing group and 1.1
in the every-4-week dosing group (least-squares
mean change, −1.1 with every-2-week dosing and
−0.7 with every-4-week dosing; P<0.001 for both
comparisons) (Fig. 1A, and Table S2 in the Supplementary Appendix); these improvements were
maintained at week 64. The reductions in the
Thacher rickets severity total score were greater
among the 34 patients who had a Thacher rickets
severity total score of 1.5 or higher at baseline,
with a least-squares mean change at week 40
of −1.7 with every-2-week dosing and −1.3 with
every-4-week dosing (Fig. 1A, and Table S3 in
the Supplementary Appendix).
The Radiographic Global Impression of Change
global score at week 40 also indicated reduction
in the severity of rickets with both dosing regimens (Fig. 1B, and Table S2 in the Supplementary Appendix). Substantial healing of rickets
(change from baseline represented by a score of
≥2.0) was achieved in 28 of 52 patients (54%) at
week 40 (18 of 26 patients in the every 2-weekdosing group and 10 of 26 patients in the every4-week dosing group) and also in 28 of 52 patients (54%) at week 64 (15 of 26 patients in the
every 2-week-dosing group and 13 of 26 patients
in the every-4-week dosing group). Among the
17 patients who had a Thacher rickets severity
total score of 1.5 or higher at baseline and were
receiving burosumab every 2 weeks, 16 patients
(94%) showed substantial healing at week 40
(Fig. 1B, and Table S3 in the Supplementary Appendix). Furthermore, when the Radiographic
Global Impression of Change scale was used to
assess overall deformities of the legs, a modest
improvement was observed at week 64 in all 52
patients (mean [±SE] score representative of
change, 0.5±0.1).
The mean fasting serum phosphorus level
increased from baseline in both groups at all
time points, with an overall mean increase of
0.75 mg per deciliter (0.24 mmol per liter; a 34%
increase) (Fig. 2A) at week 40 and 0.84 mg per
deciliter (0.27 mmol per liter; a 38% increase) at
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Table 1. Demographic and Baseline Clinical Characteristics.*
Burosumab
Every 2 Weeks
(N = 26)

Burosumab
Every 4 Weeks
(N = 26)

All Patients
(N = 52)

Mean

8.7±1.7

8.3±2.0

8.5±1.9

Range

5–12

5–12

5–12

Male sex — no. (%)

12 (46)

12 (46)

24 (46)

White race — no. (%)†

23 (88)

23 (88)

46 (88)

31.9±7.9

29.1±10.7

30.5±9.4

z Score

−1.7±1.0

−2.1±1.0

−1.9±1.00

Percentile for age and sex

11.1±13.8

6.2±8.2

8.7±11.5

17 (65)

19 (73)

36 (69)

9 (35)

7 (27)

16 (31)

24 (92)

26 (100)

50 (96)

7.0±2.1

6.7±2.6

6.9±2.4

Characteristic
Age — yr

Weight — kg
Standing height

Geographic region — no. (%)
United States
Europe
Previous conventional therapy for X-linked hypophosphatemia — no. (%)
Duration of conventional therapy — yr
Age when conventional therapy was initiated — yr
Renal tubular phosphate reabsorption — mg/dl‡§
Serum phosphorus — mg/dl§

2.2±1.5

1.9±1.2

2.1±1.3

2.2±0.5

2.0 ±0.3

2.1±0.4

2.4±0.4

2.3±0.3

2.3±0.4

Serum 1,25-dihydroxyvitamin D — pg/ml§

41.3±22.0

41.4±15.3

41.3±18.7

Serum alkaline phosphatase — U/liter§

462±110

456±101

459±105

Mean

1.9±1.2

1.7±1.0

1.8±1.1

Range

0–4.5

0–3.0

0–4.5

23 (88)

22 (85)

45 (87)

0

17 (65)

17 (65)

34 (65)

1

6 (23)

5 (19)

11 (21)

2

3 (12)

4 (15)

7 (13)

Thacher rickets severity total score¶

Positive for pathogenic PHEX mutation — no. (%)‖
Nephrocalcinosis grade — no. (%)**

*	Plus–minus values are means ±SD. To convert the values for renal tubular phosphate reabsorption to millimoles per
liter, multiply by 0.3229. To convert the values for serum phosphorus to millimoles per liter, multiply by 0.3229. To
convert the values for serum 1,25-dihydroxyvitamin D to picomoles per liter, multiply by 2.6. Percentages may not
sum to 100 because of rounding.
†	Race was determined by parent or caregiver report.
‡	Renal tubular phosphate reabsorption is expressed as the ratio of the maximum rate of tubular reabsorption of phosphate to the glomerular filtration rate.
§	Serum and urine samples for pharmacodynamic assessments were obtained during fasting.
¶	The baseline mean Thacher rickets severity total score (scores range from 0 [no rickets] to 10 [severe rickets]; scores
between 0 and 5 are typically observed in children with the form of rickets assessed in this trial) for the 16 patients
who enrolled after enrollment of the initial 36 patients was 2.63±0.72.
‖	One patient had a variant in PHEX that was considered to be probably pathogenic, and four patients had variants in
PHEX of unknown significance. No mutation in PHEX was identified in two patients; however, the analysis of mutations in PHEX cannot capture all possible mutations that alter PHEX activity. The seven patients who were not positive for pathogenic mutations in PHEX had a clinical diagnosis of X-linked hypophosphatemia and had a baseline serum intact FGF-23 level of more than 30 pg per milliliter.
**	Values range from 0 (normal) to 4 (stone formation).
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Week 64

A Thacher Rickets Severity Total Score
All Patients

Score

3.0

3.0

2.5

2.5

2.0

2.0

1.5

1.5

1.0

1.0

0.5

0.5

0.0

Every 2 Wk
(N=26)

Every 4 Wk
(N=26)

All
(N=52)

0.0

Patients with Baseline Thacher Rickets Severity
Total Score of ≥1.5

Every 2 Wk
(N=17)

Every 4 Wk
(N=17)

All
(N=34)

B Radiographic Global Impression of Change Score
All Patients

Score

3.0

3.0

2.5

2.5

2.0

2.0

1.5

1.5

1.0

1.0

0.5
0.0

Patients with Baseline Thacher Rickets Severity
Total Score of ≥1.5

0.5
1.66 1.56

1.47 1.58

1.56 1.57

Every 2 Wk
(N=26)

Every 4 Wk
(N=26)

All
(N=52)

0.0

2.02 2.06

1.80 1.90

1.91 1.98

Every 2 Wk
(N=17)

Every 4 Wk
(N=17)

All
(N=34)

C Radiographs of the Knee in an 11-Year-Old Girl
Distal Femur
Metaphyseal Lucency
Proximal Tibia

Thacher Rickets Severity Knee Score
Radiographic Global Impression of Change Global Score

week 64. By week 6, more than half the patients
in both groups had serum phosphorus levels
within the normal range (3.2 to 6.1 mg per deciliter [1.0 to 2.0 mmol per liter]). Every-2-week
dosing was associated with sustained mean increases in serum phosphorus levels during the
treatment period, whereas every-4-week dosing
showed fluctuations over time. No patients in either group had a serum phosphorus level above
the upper limit of the normal range at any time
during the trial.
The renal tubular phosphate reabsorption increased from baseline in both groups at all time
1992
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Baseline

Wk 40

Wk 64

2.0

1.0
2.0

0.0
2.3

points, with an overall mean increase of 0.98 mg
per deciliter (0.32 mmol per liter; a 51% increase)
(Fig. 2B) at week 40 and 1.01 mg per deciliter
(0.33 mmol per liter; a 51% increase) at week 64.
The mean serum 1,25-dihydroxyvitamin D level
increased from baseline in both groups at all
time points, with an overall mean increase of
23 pg per milliliter (60 pmol per liter; a 99%
increase) (Fig. 2C) at week 40 and 18 pg per milliliter (46 pmol per liter; a 78% increase) at week 64.
The mean serum alkaline phosphatase level decreased from baseline by 90 U per liter overall at
week 64 (a 20% decrease) (Fig. 2D).
nejm.org
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Figure 1 (facing page). Effects of Burosumab on Rickets
Scores.
Panel A shows the mean Thacher rickets severity total
score (scores range from 0 [no rickets] to 10 [severe
rickets]; scores between 0 and 5 are typically observed
in children with the form of rickets assessed in this trial).
All 52 patients were included in the analyses at week
40 and at week 64. A significant decrease in the Thacher
rickets severity total score was seen at week 40 in both
dosing groups (P<0.001) on the basis of the generalized
estimating equation model. Panel B shows the leastsquares mean Radiographic Global Impression of Change
score (representing the degree of change from baseline)
at week 40 and week 64. The Radiographic Global Impression of Change scale is a tool that enables a sideby-side comparison of radiographs obtained before
and after treatment and is based on a 7-point ordinal
scale: 3 (complete healing), 2 (substantial healing), 1
(minimal healing), 0 (unchanged), −1 (minimal worsening), −2 (moderate worsening), and −3 (severe worsening). Scores for the Thacher rickets severity total score
and the Radiographic Global Impression of Change are
shown for all patients and for the subgroup of patients
who had a Thacher rickets severity total score of 1.5
or higher at baseline (indicating more severe rickets).
I bars in Panels A and B indicate standard errors. Panel C
shows a set of radiographs of the knee from an 11-yearold girl who had been receiving conventional therapy
for 9 years before she was enrolled in the trial and was
randomly assigned to receive burosumab every 2 weeks.
The baseline image shows metaphyseal lucencies of
the distal femur and proximal tibia. By week 64, the abnormalities were completely healed (Thacher rickets
severity total score of 0). The Radiographic Global Impression of Change score for the knee at week 64 was
2.3, which indicated substantial healing of rickets.

The mean standing-height z score increased
from baseline in both groups, with greater improvement seen at all time points with every2-week dosing (an increase from baseline of 0.19
at week 64) than with every-4-week dosing (an
increase from baseline of 0.12 at week 64). Results are shown in Table 2, and in Figure S2A in
the Supplementary Appendix.
Across both groups, walking distance in the
6-minute walk test was increased from baseline
both at week 40 and at week 64 (Table 2). A total
of 24 of the 52 patients (46%) had an impairment (defined as a walking distance that was
<80% of the predicted normal distance) at baseline. Among these patients, the 6-minute walk
test distance increased from 68% of the predicted normal distance (408 m) at baseline to
79% of the predicted distance (487 m) at week
64 (an increase of 10%; least-squares mean increase in distance walked, 77 m); greater increasn engl j med 378;21

es were seen among the 14 patients who received
the drug every 2 weeks (12% increase; leastsquares mean increase in distance walked, 96 m)
than among the 10 patients who received the
drug every 4 weeks (8% increase; least-squares
mean increase in distance walked, 58 m) (Fig.
S2B in the Supplementary Appendix).
The baseline mean scores for the sports and
physical functioning domain and the pain and
comfort domain of the Pediatric Outcomes Data
Collection Instrument were low, defined as less
than 1 SD below the normal population mean.28
Functional ability improved and pain decreased
in both groups (Table 2). Among the 28 patients
(54% of the 52 patients) who had greater functional impairment (defined as a score of <40 on
the Global Functioning Scale) at baseline, the
score on the sports and physical functioning
domain increased by a mean of 15.6 at week 64,
and the score on the pain and comfort domain
increased by a mean of 13.4 at week 64. The results for the upper extremity, transfer and basic
mobility, and happiness domains are described
in the Supplementary Appendix.
Safety

Adverse events were reported in all 52 patients
(Table 3). One patient who received burosumab
every 4 weeks was hospitalized for serious adverse events of fever and myalgia, both of which
were assessed as being moderate in severity and
possibly related to burosumab. The fever resolved
within 24 hours after onset, the myalgia resolved
within 8 days, and the patient continued to receive treatment without recurrence of a similar
event. A total of 17 of the 26 patients (65%) in
the every-2-week dosing group and 13 of the 26
patients (50%) in the every-4-week dosing group
had an injection-site reaction; these reactions
were considered to be mild, were limited to the
skin, and lasted no more than 1 or 2 days.
Other common adverse events across the two
dosing groups were headache (26 patients), cough
(23 patients), nasopharyngitis (21 patients), and
pain in an arm or leg (21 patients). No patients
died, discontinued the trial regimen, or had doselimiting toxic effects. All adverse events reported
during the trial were mild or moderate in severity,
with the exception of a tooth abscess (in 1 patient) and a rash (in 1 patient); both events were
considered by the investigator to be unrelated to
the trial treatment.
No noteworthy changes in the levels of serum
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Every 2 wk

of

m e dic i n e

Every 4 wk

A Serum Phosphorus
4.0

Mean Value
(mg/dl)

3.5
3.0
2.5
2.0
0.0

Lower limit of normal range, 3.2 mg/dl
0

4

8

12

16

20

24

28

32

36

40

44

48

52

56

60

64

Week

B Renal Tubular Phosphate Reabsorption
4.0

Mean Value
(mg/dl)

3.6
3.2
2.8
2.4
2.0
1.6
0.0

Lower limit of normal range, 3.42 mg/dl
0

4

8

12

16

20

24

28

32

36

40

36

40

36

40

44

48

52

56

60

64

Week

C Serum 1,25-dihydroxyvitamin D
100

Mean Value
(pg/ml)

75
50
25
0

Lower limit of normal range, 43 pg/ml
0

4

8

12

16

20

24

28

32

44

48

52

56

60

64

Week

D Serum Alkaline Phosphatase

Mean Value
(U/liter)

500
450
400
350
0

Upper limit of normal range, 385 U/liter
0

4

8

12

16

20

24

28

32

44

48

52

56

60

64

Week

1994
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Table 2. Effects of Burosumab on Height, Physical Functioning, and Patient-Reported Outcomes.
Burosumab
Every 2 Weeks
(N = 26)

Burosumab
Every 4 Weeks
(N = 26)

All Patients
(N = 52)

Baseline

−1.72±1.03

−2.05±0.96

−1.89±1.00

Week 64

−1.54±1.13

−1.92±0.84

−1.73±1.00

0.19±0.05

0.12±0.06

0.15±0.04

Assessment
Standing-height z score*

Change from baseline
6-Minute walk test†
Baseline
Percentage of predicted distance

79.32±2.60

81.42±2.96

80.37±1.96

Distance (m)

479.9±16.6

486.4±21.3

483.1±13.4

Percentage of predicted distance

85.00±2.03

84.74±2.67

84.87±1.66

Change from baseline in percentage of predicted
distance — percentage points

5.69±2.02

3.32±1.96

4.50±1.41

533.85±11.51

525.85±17.56

529.85±10.41

52.67±8.82

40.59±9.57

46.63±6.48

Baseline

34.6±15.7

32.2±19.3

33.4±17.4

Week 64

41.7±15.7

42.8±13.7

42.2±14.6

7.7±2.6

9.8±2.5

8.8±1.8

Baseline

35.2±15.3

34.8±16.8

35.0±15.9

Week 64

41.0±17.0

43.0±11.5

42.0±14.5

5.6±2.9

7.7±2.1

6.7±1.8

Baseline

37.5±14.0

35.6±17.2

36.6±15.5

Week 64

43.1±16.1

45.1±11.2

44.1±13.8

6.0±2.7

8.7±2.0

7.4±1.7

Week 64

Distance (m)
Change from baseline in distance (m)
Sports and physical functioning, normative score*‡

Change from baseline
Pain and comfort scale, normative score*‡

Change from baseline
Global functioning, normative score*‡

Change from baseline

*	Plus–minus values at baseline and at week 64 are means ±SD. Plus–minus values for the change from baseline are
least-squares means ±SE.
†	Plus–minus values for the percentage of predicted distance and for distance are means ±SE. Plus–minus values for the
change from baseline are least-squares means ±SE.
‡	This variable was assessed with the use of the Pediatric Orthopedic Society of North America Pediatric Outcomes Data
Collection Instrument. The mean (±SD) population normative score is 50±10; higher scores indicate better functioning
or less pain.

Figure 2 (facing page). Effects of Burosumab on Pharmacodynamic Variables.
All serum and urine samples were obtained during fasting. A significant mean increase from baseline to week 40
in serum phosphorus level (Panel A), the renal tubular phosphate reabsorption (expressed as the ratio of the maximum rate of tubular reabsorption of phosphate to the glomerular filtration rate) (Panel B), and serum 1,25-dihydroxy
vitamin D level (Panel C) was seen among the 26 patients in each group (P<0.001). With respect to the serum alkaline phosphatase level (Panel D), there was a significant mean decrease from baseline to week 40 with every-2-week
dosing (26 patients, P<0.001) and with every-4-week dosing (26 patients, P = 0.002). Graphs displayed in SI units are
available in Figure S5 in the Supplementary Appendix. The reference range for serum alkaline phosphatase was provided by Covance Laboratories, and the reference ranges for the remaining variables were obtained from published
articles: serum phosphorus, from Lockitch et al.24; renal tubular phosphate reabsorption, from Kruse et al.23; and
1,25-dihydroxyvitamin D, from Chesney et al.22 I bars indicate standard errors.
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Table 3. Adverse Events and Antibody Results.
Burosumab
Every 2 Weeks
(N = 26)

Variable

Burosumab
Every 4 Weeks
(N = 26)

All Patients
(N = 52)

no. of patients (%)
Any adverse event

26 (100)

26 (100)

52 (100)

17 (65.4)

13 (50.0)

30 (57.7)

Adverse events with ≥15% incidence in both
groups combined
Injection-site reaction*
Headache

16 (61.5)

10 (38.5)

26 (50.0)

Cough

15 (57.7)

8 (30.8)

23 (44.2)

Nasopharyngitis

8 (30.8)

13 (50.0)

21 (40.4)

Pain in extremity

9 (34.6)

12 (46.2)

21 (40.4)

Upper respiratory tract infection

9 (34.6)

9 (34.6)

18 (34.6)

Vomiting

10 (38.5)

8 (30.8)

18 (34.6)

Arthralgia

7 (26.9)

10 (38.5)

17 (32.7)

Pyrexia

8 (30.8)

8 (30.8)

16 (30.8)

Rash

7 (26.9)

6 (23.1)

13 (25.0)

Seasonal allergy

5 (19.2)

8 (30.8)

13 (25.0)

Abdominal pain, upper

4 (15.4)

5 (19.2)

9 (17.3)

Oropharyngeal pain

3 (11.5)

6 (23.1)

9 (17.3)

Diarrhea

3 (11.5)

5 (19.2)

8 (15.4)

Nasal congestion

4 (15.4)

4 (15.4)

8 (15.4)

Nausea

5 (19.2)

3 (11.5)

8 (15.4)

Rhinorrhea

2 (7.7)

6 (23.1)

8 (15.4)

Serious adverse event

0

1 (3.8)

1 (1.9)

Leading to discontinuation of trial regimen

0

0

0

Resulting in death

0

0

0

0

0

0

Presence of antibody to burosumab

*	This category includes the following reactions at the injection site: erythema, swelling, rash, pruritus, bruising, pain,
discoloration, hematoma, hemorrhage, macule, and urticaria.

calcium, urinary calcium, or serum intact parathyroid hormone were observed (Figs. S3 and S4
in the Supplementary Appendix), and no notable
changes in vital signs occurred. Mild elevations
in serum amylase levels, primarily the salivary
isoenzyme, were detected in 13 patients at screening and in 26 patients during at least one of nine
total assessments through week 64. None of the
elevations were associated with symptoms. Evaluation of renal ultrasonographic images to detect nephrocalcinosis revealed no change from
baseline in renal ultrasound scores (0 [normal]
to 4 [stone formation]19,29) in 21 patients in each
group; of the remaining patients, 1 patient in
each group had a decrease in score from 1 to 0
and 3 patients in each group had an increase in
score from 0 to 1, 1 to 2, or 2 to 3. Ultrasono1996

n engl j med 378;21

graphic data from 2 patients were missing. No
patient had a change in renal ultrasound score
of more than 1 point. Renal function remained
normal. There was no evidence of ectopic myocardial mineralization on echocardiography. No
antibodies to burosumab were detected at any
postbaseline visits. The mean dose of burosumab
at week 40 was 0.98 mg per kilogram with every2-week dosing and 1.50 mg per kilogram with
every-4-week dosing.

Discussion
In the current trial, inhibition of FGF-23 activity
with burosumab, a recombinant human IgG1
monoclonal antibody, was associated with an
increase in renal tubular phosphate reabsorption
nejm.org
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and the correction of hypophosphatemia in children with X-linked hypophosphatemia. The improvement in phosphate metabolism corresponded to a decrease in the severity of rickets. The
healing of rickets probably contributed to concurrent improvements in growth and physical
activity and a reduction in pain.
Treatment with burosumab administered once
every 2 weeks provided a sustained increase in
the serum phosphorus level to normal or nearnormal levels after the dose was adjusted to approximately 1 mg per kilogram, whereas every4-week dosing was associated with lower levels
of serum phosphorus at the end of the dose interval. Pharmacodynamic results showed a plateaued treatment response, which suggested that
feedback mechanisms may stabilize the levels of
serum phosphorus and 1,25-dihydroxyvitamin D
when the duration of exposure is longer or the
dose levels are higher. Every-2-week dosing resulted in substantial healing of rickets in nearly
all the children who had more severe rickets at
baseline. These results indicate that burosumab
at a dose of approximately 1.0 mg per kilogram
administered every 2 weeks is an appropriate
regimen for improving renal tubular phosphate
reabsorption and clinical outcomes in children
with X-linked hypophosphatemia.
Small but significant amelioration of leg deformity, as assessed by scores on the Radiographic
Global Impression of Change, were observed.
Studies in animals suggest that normalization of
the ambient phosphate milieu may correct the
disrupted cellular organization of the rachitic
growth plate to allow for improved growth.30-33
In children with X-linked hypophosphatemia,
ongoing management of the disease is critical to
elicit the best possible skeletal outcomes; therefore, a placebo control group was deemed to be
unacceptable, given the duration of the current
trial. An active control group was not included
in the trial owing to the lack of clinical data
regarding burosumab or conventional therapy
and to the considerable variability in the application of conventional therapy.1 Despite the lack of
a control group, the consistent improvement in
the fasting serum phosphorus response that was
observed in all the patients coincided with improvements in multiple related efficacy end points,
including amelioration of rickets, increase in
linear growth, improvement in physical ability,
and reduction in pain. These findings suggest a
therapeutic benefit in a pediatric population
n engl j med 378;21

with X-linked hypophosphatemia in which almost
all the patients had previously received conventional therapy with limited clinical improvement. On the basis of the findings from this
trial, a phase 3 trial (ClinicalTrials.gov number,
NCT02915705), which is ongoing, was designed
to investigate the efficacy and safety of burosumab as compared with conventional therapy.
No clinically significant safety findings with
burosumab were observed during the current
trial. The most commonly reported adverse
events were either typical for children or were
common manifestations of X-linked hypophosphatemia.1,34-38 Hyperphosphatemia was not observed in any patient during treatment. Moreover, no noteworthy changes in levels of serum
calcium, urinary calcium, or serum intact parathyroid hormone were noted, and no antibodies
to burosumab were detected after treatment.
For more than 40 years, treatment for X-linked
hypophosphatemia has consisted of multiple
daily doses of oral phosphate salts and active
vitamin D. This approach is often difficult to
maintain, particularly in younger patients, owing
to the burdens of multiple daily dosing, parental
surveillance, and suboptimal phosphate preparations.5 The limitations of conventional therapy
are evidenced by the persistence of rickets observed in radiographs obtained at screening in
this trial despite the patients having received
therapy for X-linked hypophosphatemia at academic specialty centers for multiple years.1,5,6 By
targeting a central pathophysiological defect in
X-linked hypophosphatemia (i.e., excess FGF-23),
burosumab improved phosphate homeostasis and
decreased the severity of rickets.
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